The uses and therapeutic benefits of Инвокана (Canagliflozin) may be part of symptomatic management for patients with Type 2 Diabetes Mellitus, easing symptoms related to systemic imbalance and addressing clinical risk factors.

The medicine is applied across domains where additional symptomatic support is needed. It is commonly used to help with managing elevated blood sugar (HbA1c and plasma glucose), is considered relevant for easing the risk of major cardiovascular events (such as heart attack or stroke), and the progression of diabetic kidney disease.

The key benefit may assist with maintaining functional stability, which contributes to improved comfort during periods of heightened symptoms. It is relevant when symptoms associated with chronic conditions create noticeable physiological strain.

---

Supportive Focus: Addressing Systemic Strain

Инвокана is considered relevant for easing symptoms linked to organ-specific functional stress in the kidneys and heart. This action supports patients during episodes of heightened discomfort by easing distress, which assists with maintaining functional stability.

Eligibility Map: Who can and cannot use Инвокана (Canagliflozin) — Official Regulatory Information

Official regulatory documents define specific patient populations that are approved to use Инвокана and those for whom use is restricted or prohibited.

Classification	Eligibility Rule (Based on Regulatory Label)
Approved Populations	Adults and pediatric patients aged 10 years and older with Type 2 Diabetes Mellitus.
Absolute Contraindication	History of a serious hypersensitivity reaction to Canagliflozin, such as anaphylaxis or angioedema.
Not Recommended Use	Treatment of Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA).
Organ Function Restrictions	Severe hepatic impairment and severe renal impairment (eGFR <30 mL/ min/1.73 m^2) for improving glycemic control.
Pregnancy/Lactation	Not recommended during the second and third trimesters of pregnancy or while breastfeeding.
Age Restriction	Safety and effectiveness have not been established in children younger than 10 years of age.

Eligibility is also restricted by moderate renal impairment (eGFR 45 to <60 mL/ min/1.73 m^2). Initiation is not recommended if eGFR is persistently less than 45 mL/ min/1.73 m^2.

Interactions with other medicines and products

Official regulatory documents detail specific interactions for Invokana (Canagliflozin) that affect either its concentration in the body or the concentration of co-administered medicines.

---

Effects on Canagliflozin Exposure

• Enzyme Inducers: Co-administration with strong UGT enzyme inducers, such as Rifampin, reduces the systemic exposure (plasma concentration) of Canagliflozin. Other enzyme inducers, including Phenytoin and Phenobarbital, may have a similar effect.
• Transporter Inhibitors: Medicines that inhibit the P-glycoprotein (P-gp) or OATP1B1/1B3 transporters, such as Ketoconazole, may increase the systemic exposure of Canagliflozin.

---

Interactions Affecting Other Medicines

• Digoxin: Canagliflozin increases the systemic exposure ( AUC and C max) of Digoxin (a P-gp substrate).
• Lithium: Canagliflozin’s effect on sodium excretion may lead to a decrease in Lithium serum concentrations.

---

️ Pharmacodynamic Considerations

• Diuretics: Co-administration with diuretics (e.g., Furosemide) may increase the risk of symptomatic volume depletion and hypotension. This risk is noted as particularly relevant for patients with pre-existing renal impairment.
• Insulin and Sulfonylureas: Combining Canagliflozin with Insulin or Sulfonylureas may increase the risk of hypoglycemia (low blood sugar) due to their additive effects on glucose lowering.

Official labeling does not specify any formally contraindicated drug combinations based on interaction risk alone, nor does it mandate specific time separation requirements for administration.

Инвокана (Canagliflozin) functions as a competitive and reversible inhibitor primarily targeting the sodium-glucose cotransporter 2 (SGLT2) protein. This protein is predominantly expressed on the apical membrane of epithelial cells in the renal proximal tubules .

By inhibiting SGLT2, the drug reduces the active transport-mediated reabsorption of filtered glucose from the tubular lumen back into the systemic circulation. This molecular action decreases the renal threshold for glucose (RTG). Downstream, the intracellular consequence is a diminished capacity for glucose salvage in the tubule cells.

System-level physiological consequences include a dose-dependent increase in urinary glucose excretion (glucosuria), along with associated osmotic diuresis and natriuresis due to the co-transported sodium remaining in the filtrate. Canagliflozin exhibits approximately 150-fold selectivity for SGLT2 over SGLT1, though transient, lower-potency inhibition of SGLT1 in the intestinal brush border has also been observed, leading to delayed intestinal glucose absorption.

How to Use Инвокана

The use of Инвокана (Canagliflozin) is governed by specific guidelines that define its administration route, standardized dosing schedule, and required timing. The medicine is supplied as a film-coated tablet and is intended exclusively for oral administration. To ensure proper use, the tablet must be swallowed whole with water and should not be crushed, chewed, or split.

---

Official Dosing and Schedule

The standardized regimen requires the medicine to be taken once daily. The typical starting and maintenance dose is 100 mg, which is to be administered specifically before the first meal of the day. The highest authorized intake is the maximum recommended dose of 300 mg once daily. If a daily dose is missed, the protocol is to take it immediately unless it is almost time for the next scheduled dose, in which case the missed dose is skipped, and a double dose must not be taken.

---

Population-Specific Dosing Boundaries

A critical procedural constraint on the use of Инвокана is a patient’s kidney function. For individuals with moderate renal impairment, the maximum permitted daily dose is restricted to 100 mg. Furthermore, the administration of the medicine is generally not recommended below certain specified thresholds of kidney function. These guidelines establish the procedural boundaries for administering the medicine in specific populations.

Canagliflozin: Recent Clinical Evidence

Canagliflozin (marketed as Invokana) is an oral medication approved for treating type 2 diabetes mellitus. It belongs to the class of sodium-glucose cotransporter 2 (SGLT2) inhibitors.

---

Clinical Trial Overview

Research has primarily investigated canagliflozin's effect on glycemic control and its associated outcomes in large-scale clinical programs, including the CANVAS Program (Canagliflozin Cardiovascular Assessment Study) and CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation).

These large, randomized, placebo-controlled trials explored its use in adult patients with type 2 diabetes, often those who had established cardiovascular disease (CVD) or were at high risk for kidney disease.

---

Key Findings

Area of Study	Key Reported Findings
Cardiovascular Risk	Studies found that canagliflozin was associated with a reduction in the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established CVD.
Renal (Kidney) Outcomes	Research explored whether canagliflozin was associated with a reduced risk of kidney failure and the progression of diabetic nephropathy in patients with established chronic kidney disease.
Glycemic Control	Trials reported an association between canagliflozin and lower HbA1c levels (a measure of average blood sugar), which persisted through the study periods.

Further research continues to investigate the full range of associations and potential benefits of SGLT2 inhibitors in diverse patient populations.

Common questions about Инвокана (FAQ)

Q: What is Invokana (Canagliflozin) and how does it work?

Invokana is a prescription medication used to improve blood sugar control in adults with Type 2 diabetes mellitus. It belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors.

It works by blocking the SGLT2 protein in the kidneys. This protein is responsible for reabsorbing glucose back into the blood. By blocking it, Invokana causes the kidneys to remove more glucose from the blood and excrete it through the urine, which helps lower blood sugar levels.

Q: What is the generic name for Invokana?

The generic name for Invokana is Canagliflozin.

Q: Is Invokana a form of insulin?

No, Invokana (Canagliflozin) is not a form of insulin. It works differently than insulin. It belongs to the SGLT2 inhibitor class and helps the kidneys excrete excess glucose in the urine. It can be used alone or in combination with other diabetes medications, including insulin, as prescribed by a healthcare provider.

Q: What are the primary uses of Invokana?

Invokana is primarily used to:

• Improve blood sugar (glucose) control in adults with Type 2 diabetes mellitus.
• Reduce the risk of major adverse cardiovascular (CV) events like heart attack, stroke, or death in adults with Type 2 diabetes and established CV disease.
• Reduce the risk of developing end-stage kidney disease, worsening kidney function, or CV death in adults with Type 2 diabetes and diabetic nephropathy (kidney damage caused by diabetes).

Q: How long does it take for Invokana to start working?

Invokana begins to lower blood glucose levels shortly after starting treatment. However, the full effect on A1C (a measure of average blood sugar over two to three months) and its long-term benefits for heart and kidney protection may take several weeks or months to become fully apparent. Your healthcare provider will monitor your blood sugar and A1C to assess its effectiveness.

Q: Does Invokana cause weight loss?

Many people taking Invokana experience modest weight loss. This effect is thought to be related to the loss of calories through the glucose excreted in the urine. However, Invokana is not a weight-loss medication, and the amount of weight lost can vary among individuals.

Q: Can Invokana be taken with or without food?

Invokana should be taken once daily, before the first meal of the day. Taking it before the first meal helps maximize the medication's effect in reducing glucose absorption and is recommended for best results.

Q: What are some of the common side effects of Invokana?

Common side effects of Invokana may include:

• Genital yeast infections (in both women and men)
• Urinary tract infections (UTIs)
• Increased urination
• Thirst or dehydration
• Constipation
• Changes in cholesterol levels

It is important to discuss any side effects with a healthcare provider.

Q: Are there any serious side effects associated with Invokana?

Yes, Invokana is associated with a few serious side effects, though they are less common. These may include:

• Diabetic ketoacidosis (DKA), which is a serious condition requiring immediate medical attention.
• Serious urinary tract infections that could spread and cause kidney problems.
• Lower limb amputations (this is a rare but serious risk, particularly in those with pre-existing vascular disease or neuropathy).
• Dehydration and hypotension (low blood pressure), especially in older adults or those taking diuretics.
• Necrotizing fasciitis of the perineum (Fournier’s gangrene), a rare but life-threatening bacterial infection.

Patients should be aware of the symptoms and contact their healthcare provider immediately if they experience signs of DKA, severe UTI, or other serious symptoms.

Q: Can I drink alcohol while taking Invokana?

Drinking alcohol while taking Invokana should be discussed with a healthcare provider. Alcohol can lower blood sugar and increase the risk of hypoglycemia (especially when combined with other diabetes medications). Additionally, heavy alcohol use may increase the risk of diabetic ketoacidosis (DKA).

Q: Is Invokana safe to take during pregnancy or while breastfeeding?

The safety of Invokana during pregnancy has not been fully established, and it is generally not recommended in the second and third trimesters. It is also not recommended for use while breastfeeding as it may pass into breast milk.

Patients who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider for advice on managing their diabetes.

Q: Does Invokana interact with other medications?

Invokana may interact with several other medications. Key interactions include:

• Diuretics (water pills): May increase the risk of dehydration and low blood pressure.
• Insulin and insulin secretagogues (like sulfonylureas): May increase the risk of hypoglycemia (low blood sugar).
• Digoxin (for heart failure): Invokana may increase the concentration of digoxin in the blood.
• Rifampin (an antibiotic) and certain other drugs: May reduce the effectiveness of Invokana.

It is crucial for patients to inform their healthcare provider and pharmacist about all medications, vitamins, and herbal supplements they are taking to check for potential interactions.

Q: What should I do if I miss a dose of Invokana?

If you miss a dose of Invokana, take it as soon as you remember, but only if it is still before your first meal of the day. If you do not remember until later in the day, skip the missed dose and take your next dose at the regular time the next day. Do not take two doses at the same time to make up for a missed dose. If you are unsure, consult your healthcare provider.

Q: Does Invokana affect blood pressure?

Invokana can sometimes cause a mild reduction in blood pressure. This is generally a result of the diuretic effect (increased urination). This effect may be beneficial for some patients with Type 2 diabetes who also have hypertension. However, it can also lead to hypotension (low blood pressure), especially in patients already taking diuretics or those at risk of dehydration. Blood pressure should be monitored regularly.

How to Store and Dispose of Invokana (Canagliflozin)

Invokana tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product is stable within a range of 15 C to 30 C (59 F to 86 F). Storage must ensure the medicine remains out of the sight and reach of children.

Disposal Requirements

Unused or expired Invokana should be discarded according to official instructions to prevent environmental contamination. The tablets must not be flushed down the toilet or disposed of in household drains. Patients should utilize a medicine take-back program if one is available in their area, or follow local governmental guidelines for discarding pharmaceutical waste.